Evaluation of Levamisole efficacy in treatment of Covid-19

Phase 2

Recruiting

Conditions: COVID-19.
Coronavirus infection, unspecified
B34.2

Registration Number: IRCT20190810044500N7

Lead Sponsor: Yazd University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 50

Inclusion Criteria

Ages 18 to 60 years
Diagnosis of Covid-19 over the past 24 hours
Female patients are not exposed to pregnancy and do not become pregnant until thirty days later.
Not taking levamisole for the past five days (due to 16-hour drug half-life)
Patients suspected to covid-19 based on clinical signs and symptoms of CT scan and candidate for outpatient treatment
No medication other than protocol
No underlying disease

Exclusion Criteria

Hospitalized Patients
Patients with hemodynamic instability
History of cirrhosis, hepatitis and severe liver disease, severe renal failure (less than 30ml / min)
Patients currently taking levamisole for other uses such as parasitic infection
Patients with a history of allergic reaction or sensitivity to levamisole
Patients receiving chemotherapy for cancer
Pregnancy and lactation
Ages less than 18 years and over 60 years
Patients with underlying diseases including diabetes and hypertension

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical symptoms include fever, cough, shortness of breath. Timepoint: Before the intervention, after completion of the intervention. Method of measurement: Clinical examination.;Patients need to be hospitalized. Timepoint: Before the intervention, after completion of the intervention. Method of measurement: Clinical examination.

Secondary Outcome Measures

Name	Time	Method
Mortality. Timepoint: after completion of the intervention. Method of measurement: Clinical examination.;Side effects that occur during treatment or severe side effects that lead to discontinuation of treatment. Timepoint: Before the intervention, after completion of the intervention. Method of measurement: Clinical examination.